Evogene Schedules First Quarter 2026 Financial Results Release
Rhea-AI Summary
Evogene (NASDAQ: EVGN) will release its Q1 2026 financial results on Wednesday, May 20, 2026. Management will host a live Zoom conference call the same day at 9:00 AM ET (4:00 PM Israel). Registration is required: https://www.veidan-conferencing.com/evogene. A replay will be posted on the company's website a few days after the call.
Positive
- None.
Negative
- None.
News Market Reaction – EVGN
In the May 7 session, EVGN declined 1.31%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Earnings results | Negative | -6.2% | Reported 2025 results with continued operating and net losses plus restructuring. |
| Feb 19 | Earnings scheduling | Neutral | -5.6% | Announced date and call details for Q4 and full-year 2025 results. |
| Nov 06 | Earnings scheduling | Neutral | -1.7% | Set timetable and Zoom call for Q3 2025 financial results release. |
| Aug 19 | Earnings results | Neutral | -4.2% | Reported Q2 2025 results with higher H1 revenue and lower expenses amid restructuring. |
| Jul 29 | Earnings scheduling | Neutral | -2.3% | Announced Q2 2025 results date and investor conference call logistics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-related announcements have often coincided with negative next-day moves, even when merely scheduling results.
Over the past year, Evogene’s earnings-related news has generally been followed by modest declines. Actual results on Mar 5, 2026 saw a -6.16% reaction amid ongoing losses and restructuring. Prior result releases and scheduling notices in 2025–2026 around Q2, Q3, and full-year updates produced single‑day moves between roughly -1.69% and -5.57%. Today’s Q1 2026 scheduling fits this pattern of frequent financial updates against a challenging operating backdrop.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Zoom conference call scheduled for May 20, 2026, 9:00 AM ET
REHOVOT,
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To attend the conference, please register in advance:
https://www.veidan-conferencing.com/evogene
The entire conference will be available online on the company's website a few days after.
About Evogene:
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products.
At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com.
Contact
ir@evogene.com
Tel: +972-8-9311901
Logo: https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-schedules-first-quarter-2026-financial-results-release-302765447.html
SOURCE Evogene